Sugi Predict

Sugi Predict / Compounds / SCHEMBL1019278

SCHEMBL1019278

SCHEMBL1019278

OCc1cc(B(O)O)ccc1F

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 5/20 0.44
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ MAPK1 P28482 1/20 0.35
▸ MAP2K4 P45985 1/20 0.35
▸ MAPKAPK2 P49137 1/20 0.35
▸ MAPKAPK3 Q16644 1/20 0.35
▸ MAPK6 Q16659 1/20 0.35
▸ EGFR P00533 1/20 0.35
▸ MGLL Q99685 2/20 0.34
▸ LPL P06858 1/20 0.34
▸ LIPG Q9Y5X9 1/20 0.34
▸ TTR P02766 1/20 0.34
▸ TSHR P16473 1/20 0.33
▸ F11 P03951 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29951218 1.00 ENPP2 (0.44) ENPP2CA1CA2MAPK1MAP2K4
SCHEMBL15738778 0.83 ENPP2 (0.44) ENPP2CA1CA2MGLLLPL
SCHEMBL17339405 0.82 F11 (0.45) ENPP2CA1CA2MGLLTTR
SCHEMBL3082470 0.82 LPL (0.47) ENPP2CA1CA2LPLLIPG
SCHEMBL3780619 0.80 ENPP2 (0.48) ENPP2CA1CA2LPLLIPG
SCHEMBL18705814 0.79 KDM4E (0.45) ENPP2CA1CA2MAPK1LPL
SCHEMBL5688518 0.77 ENPP2 (0.38) ENPP2CA1CA2LPLLIPG
SCHEMBL16576645 0.77 RIPK1 (0.35) ENPP2CA1CA2EGFRMGLL
Hydrochloric Acid SCHEMBL20768995 0.77 KDM4E (0.44) LPLLIPGF11
SCHEMBL22249682 0.77 ENPP2 (0.34) ENPP2CA1CA2MGLLLPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115477741-B Degradable polymer and preparation method and application thereof 浙江中医药大学 2023-08-18 — — CN claimed
CN-115477741-A Degradable polymer and preparation method and application thereof 浙江中医药大学 2022-12-16 — — CN claimed
US-20260124201-A1 CYCLOPENTANE COMPOUND KISSEI PHARMACEUTICAL CO., LTD. (JP) 2026-05-07 — — US disclosed
US-12404253-B2 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 ASTRAZENECA AB (SE) 2025-09-02 — — US disclosed
EP-4600242-A1 CYCLOPENTANE COMPOUND Kissei Pharmaceutical Co., Ltd. (JP) 2025-08-13 — — EP disclosed
US-12378250-B2 Tricyclic compound as IRAK4 inhibitor KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-08-05 — — US disclosed
EP-3885348-B1 NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR KOREA RES INST CHEMICAL TECH (KR) 2025-02-12 — — EP disclosed
US-20240383866-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 ASTRAZENECA AB (SE) 2024-11-21 — — US disclosed
US-12036292-B2 Heterobiaryl compounds and imaging agents for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2024-07-16 — — US disclosed
US-20240199558-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 ASTRAZENECA AB (SE) 2024-06-20 — — US disclosed
WO-2024075825-A1 CYCLOPENTANE COMPOUND キッセイ薬品工業株式会社 2024-04-11 — — WO disclosed
US-6919353-B2 Substituted 8-arylquinolune PDE4 inhibitors MERCK FROSST CANADA & CO. (CA) 2005-07-19 — — US disclosed
EP-1404330-B1 SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA INC (CA) 2005-06-01 — — EP disclosed
EP-1517895-A1 8-(BIARYL) QUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA INC. (CA) 2005-03-30 — — EP disclosed
EP-1487797-A1 HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS Merck Frosst Canada & Co. (CA) 2004-12-22 — — EP disclosed
US-20040162314-A1 Substituted 8-arylquinolune pde4 inhibitors MERCK FROSST CANADA LTD. (CA) 2004-08-19 — — US disclosed
EP-1404330-A1 SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS Merck Frosst Canada & Co. (CA) 2004-04-07 — — EP disclosed
WO-2004000814-A1 8-(BIARYL) QUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-12-31 — — WO disclosed
WO-2003078397-A1 HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-09-25 — — WO disclosed
WO-2003002118-A1 SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199558-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 CX3CR1, CCR2, CCR5 ENPP2 1072/4885CA1 4630/4885CA2 4409/4885
US-20040162314-A1 Substituted 8-arylquinolune pde4 inhibitors PDE12, PDE4A, PDE4B ENPP2 941/4885CA1 4059/4885CA2 2338/4885
US-20240383866-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 CX3CR1, CCR2, CCR5 ENPP2 1072/4885CA1 4630/4885CA2 4409/4885
US-12404253-B2 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 CX3CR1, CCR2, CCR5 ENPP2 1072/4885CA1 4630/4885CA2 4409/4885
US-12378250-B2 Tricyclic compound as IRAK4 inhibitor IRAK4, IRAK1, IRAK2 ENPP2 2259/4885CA1 2727/4885CA2 2097/4885
US-12036292-B2 Heterobiaryl compounds and imaging agents for imaging huntingtin protein HTT, HYPK, ATXN2L ENPP2 1218/4885CA1 2103/4885CA2 3471/4885
US-20260124201-A1 CYCLOPENTANE COMPOUND HCRTR1, HCRTR2, CNR1 ENPP2 870/4885CA1 1032/4885CA2 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.